The mean (±SD) time since the diagnosis of secondary progressive multiple sclerosis was 7.9±7.3 years in the tolebrutinib group and 8.4±7.8 years in the placebo group, and the time since the ...

event-driven trials (GEMINI 1 and GEMINI 2), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive tolebrutinib (60 mg once daily) or teriflunomide (14 mg ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

A Cleveland Clinic-led clinical trial of tolebrutinib ... in patients with non-relapsing secondary progressive multiple sclerosis (SPMS). The first peer-reviewed results of the Phase 3 HERCULES ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis ... PRLs in Tolebrutinib Trials At ACTRIMS, Oh ...

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation ...